Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeVRTXVertex Pharmaceuticals$495.42+1.4%$453.85$377.85▼$519.88$127.22B0.411.49 million shs1.37 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceVRTXVertex Pharmaceuticals+1.45%+0.77%+5.42%+6.74%+20.12%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationVRTXVertex Pharmaceuticals3.8272 of 5 stars2.33.00.03.32.92.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceVRTXVertex Pharmaceuticals 2.65Moderate Buy$506.702.28% UpsideCurrent Analyst Ratings BreakdownLatest VRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/20/2025VRTXVertex PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$407.00 ➝ $408.002/11/2025VRTXVertex PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Hold$408.00 ➝ $424.002/11/2025VRTXVertex PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$460.00 ➝ $520.002/11/2025VRTXVertex PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$402.00 ➝ $407.002/11/2025VRTXVertex PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$435.00 ➝ $467.002/11/2025VRTXVertex PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$480.00 ➝ $480.002/11/2025VRTXVertex PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$433.00 ➝ $450.002/11/2025VRTXVertex PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/11/2025VRTXVertex PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$450.00 ➝ $459.002/11/2025VRTXVertex PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$550.00 ➝ $550.00(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookVRTXVertex Pharmaceuticals$11.02B11.54N/AN/A$63.90 per share7.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateVRTXVertex Pharmaceuticals-$535.60M-$2.20N/A28.292.11-4.86%-2.02%-1.49%5/5/2025 (Estimated)Latest VRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/10/2025Q4 2024VRTXVertex Pharmaceuticals$3.99$3.54-$0.45$3.50$2.78 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioVRTXVertex Pharmaceuticals0.012.692.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipVRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipVRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableVRTXVertex Pharmaceuticals6,100256.79 million256.28 millionOptionableVRTX HeadlinesRecent News About These CompaniesTredje AP fonden Has $55.35 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 13 at 5:49 AM | marketbeat.comVestcor Inc Sells 12,624 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 13 at 5:48 AM | marketbeat.comSwiss National Bank Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 13 at 5:39 AM | marketbeat.com630 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Natural Investments LLCMarch 13 at 4:35 AM | marketbeat.comVertex Pharmaceuticals (NASDAQ:VRTX) Upgraded at StockNews.comMarch 12 at 11:14 PM | marketbeat.comVertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to KnowMarch 12 at 8:42 PM | msn.comWhy Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?March 12 at 3:40 PM | msn.comWhy Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge FundsMarch 12 at 2:57 PM | insidermonkey.comShould You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio?March 12 at 9:35 AM | insidermonkey.com15,528 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Wealth High Governance Capital LtdaMarch 12 at 6:22 AM | marketbeat.comWealthfront Advisers LLC Buys 32,997 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 12 at 5:43 AM | marketbeat.comVertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to "Buy" at StockNews.comMarch 12 at 4:09 AM | americanbankingnews.com11 Best Pharma Stocks to Buy According to Hedge FundsMarch 11 at 9:20 PM | insidermonkey.com3 Reasons to Avoid VRTX and 1 Stock to Buy InsteadMarch 11 at 4:18 PM | finance.yahoo.comCitizens Financial Group Inc. RI Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 11 at 6:02 AM | marketbeat.comNasdaq Correction: The 2 Smartest Stocks to Buy and Hold ForeverMarch 11 at 5:31 AM | fool.comClare Market Investments LLC Acquires New Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 11 at 5:25 AM | marketbeat.comWhere Will Vertex Pharmaceuticals Be in 10 Years?March 11 at 4:25 AM | fool.comRep. Jefferson Shreve Purchases Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)March 11 at 2:04 AM | marketbeat.comVertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)March 10 at 3:34 PM | seekingalpha.comIf I Could Buy Only 1 Growth Stock, This Would Be ItMarch 10 at 9:00 AM | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRTX Company DescriptionsVertex Pharmaceuticals NASDAQ:VRTX$495.42 +7.08 (+1.45%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$494.20 -1.22 (-0.25%) As of 03/12/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
